Embecta Corp. (NASDAQ:EMBC) Shares Bought by Yacktman Asset Management LP

Yacktman Asset Management LP lifted its position in shares of Embecta Corp. (NASDAQ:EMBC) by 0.8% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 2,671,237 shares of the company’s stock after buying an additional 20,296 shares during the period. Yacktman Asset Management LP owned 4.64% of Embecta worth $50,567,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Embecta by 2.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,564 shares of the company’s stock worth $460,000 after purchasing an additional 834 shares during the period. Cavalier Investments LLC grew its holdings in Embecta by 3.8% in the 3rd quarter. Cavalier Investments LLC now owns 23,012 shares of the company’s stock valued at $346,000 after buying an additional 839 shares during the period. Public Employees Retirement System of Ohio increased its stake in shares of Embecta by 66.2% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 2,284 shares of the company’s stock valued at $34,000 after acquiring an additional 910 shares during the last quarter. Dark Forest Capital Management LP lifted its holdings in shares of Embecta by 2.0% during the 3rd quarter. Dark Forest Capital Management LP now owns 48,430 shares of the company’s stock worth $729,000 after acquiring an additional 943 shares during the period. Finally, Swiss National Bank boosted its position in shares of Embecta by 0.9% in the third quarter. Swiss National Bank now owns 125,920 shares of the company’s stock worth $1,895,000 after acquiring an additional 1,100 shares during the last quarter. Institutional investors and hedge funds own 93.83% of the company’s stock.

Insider Buying and Selling

In other news, Director David F. Melcher acquired 2,000 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were bought at an average price of $16.25 per share, for a total transaction of $32,500.00. Following the completion of the purchase, the director now directly owns 45,080 shares of the company’s stock, valued at approximately $732,550. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.28% of the stock is currently owned by corporate insiders.

Embecta Stock Down 0.4 %

Shares of NASDAQ EMBC traded down $0.04 during trading on Friday, hitting $10.36. 136,032 shares of the company traded hands, compared to its average volume of 408,821. The firm has a market capitalization of $596.53 million, a P/E ratio of 10.95 and a beta of 0.73. The company has a 50-day moving average price of $12.81 and a 200-day moving average price of $15.45. Embecta Corp. has a 1 year low of $9.93 and a 1 year high of $32.00.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings results on Friday, February 9th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.46 by $0.15. Embecta had a net margin of 4.93% and a negative return on equity of 18.66%. The firm had revenue of $277.30 million for the quarter, compared to analyst estimates of $264.92 million. During the same quarter last year, the firm posted $0.93 earnings per share. Embecta’s revenue for the quarter was up .6% compared to the same quarter last year. Research analysts predict that Embecta Corp. will post 2.14 EPS for the current fiscal year.

Embecta Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Wednesday, February 28th were issued a dividend of $0.15 per share. The ex-dividend date of this dividend was Tuesday, February 27th. This represents a $0.60 annualized dividend and a dividend yield of 5.79%. Embecta’s payout ratio is currently 63.16%.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.